Why Did Oxford Nanopore Technologies PLC (LSE:ONT) Shares Rise 2.21% Today?
As of 28 July 2026, Oxford Nanopore Technologies PLC (LSE:ONT) shares were up 2.21%, with investors continuing to assess the company's mixed but strategically important 13 July half-year trading update.
The update initially disappointed the market because H1 2026 revenue of approximately £116.5 million was below management's expectations. Revenue nevertheless increased around 10% on a reported basis and 12% at constant currency, while weakness was concentrated particularly in China and the Middle East.
Importantly, Oxford Nanopore maintained its FY2026 guidance for 21–25% constant-currency revenue growth, supported partly by additional collaboration and licensing opportunities expected during H2. Management also reiterated its expectation of achieving adjusted EBITDA breakeven during FY2027.
There was no major new operating announcement identified on 28 July itself. Therefore, the 2.21% increase appears more consistent with recovery from the sharp post-trading-update sell-off, confidence in strong Clinical and BioPharma growth, and positioning ahead of the 19 August interim results rather than a fresh same-day catalyst.
Key Highlights
Oxford Nanopore expects H1 2026 revenue of approximately £116.5 million, representing 10% reported growth and 12% constant-currency growth.
Applied Markets revenue increased approximately 22%, led by 35% Clinical growth and 25% BioPharma growth.
PromethION revenue increased approximately 15% year-on-year, demonstrating continued adoption of the company's higher-throughput sequencing platform.
Management maintained FY2026 constant-currency revenue-growth guidance of approximately 21–25% and gross-margin guidance of around 62%.
Oxford Nanopore continues to target adjusted EBITDA breakeven during FY2027.
The next major catalyst is the company's H1 results on 19 August 2026.
About Oxford Nanopore Technologies PLC
Oxford Nanopore Technologies develops a new generation of nanopore-based molecular sensing technology.
Its platform enables real-time, scalable analysis of DNA and RNA, with technology also being developed for protein analysis.
Oxford Nanopore's systems range from portable sequencing devices through to high-throughput platforms designed for larger laboratories.
The technology is used in more than 125 countries across research and applications involving humans, animals, plants, bacteria, viruses and environmental samples.
Why Did Oxford Nanopore Shares Rise 2.21% Today?
The key point is that there does not appear to have been a major new earnings announcement on 28 July 2026.
Instead, investors are still processing the company's 13 July trading update.
That update triggered a sharp negative initial reaction: Oxford Nanopore shares fell around 18% in early trading on 13 July after management acknowledged that H1 revenue had fallen below expectations.
This creates an important context for today's increase.
A stock that falls sharply after disappointing news can subsequently recover as investors reassess whether the original decline fully reflects the company's longer-term prospects.
Oxford Nanopore maintained its full-year guidance and reported particularly strong growth in Clinical and BioPharma applications.
Therefore, the 2.21% increase appears more consistent with a partial recovery and renewed focus on the stronger parts of the business.
H1 Revenue Reached Approximately £116.5 Million
Oxford Nanopore expects to report approximately £116.5 million of first-half revenue.
That represents:
10% reported growth
and
12% constant-currency growth.
The problem was not that revenue declined.
Instead, growth came in below management's own expectations.
This distinction matters when evaluating the investment case.
Oxford Nanopore remains a growing company, but investors had expected faster expansion.
China Was a Major Source of Weakness
China represented one of the biggest problems during H1.
Revenue in the country declined approximately 16%.
Management attributed this to enhanced export-control restrictions and changes to its commercial operations in the region.
This creates uncertainty because geopolitical and regulatory factors can be difficult for an individual company to control.
If restrictions persist, China could remain a drag on group growth.
However, performance elsewhere was considerably stronger.
Middle East Revenue Fell 14%
Revenue in the Middle East declined approximately 14%, reflecting ongoing geopolitical disruption.
Again, this appears more related to regional operating conditions than fundamental deterioration in the underlying technology.
Importantly, Oxford Nanopore said that excluding China and the Middle East, group revenue increased approximately 16% at constant currency.
That figure provides a clearer indication of underlying momentum across many of the company's other markets.
EMEAI Delivered 23% Growth
Europe, the Middle East, Africa and India collectively delivered approximately 23% constant-currency growth despite the Middle Eastern disruption.
Growth was supported by Clinical and BioPharma applications.
This is particularly encouraging because these markets could ultimately become much larger commercial opportunities than traditional academic research alone.
Greater adoption in healthcare and pharmaceutical applications could significantly expand Oxford Nanopore's addressable market.
Americas Revenue Increased 12%
The Americas delivered approximately 12% constant-currency growth.
Management said performance remained positive, although growth was slower than expected because of the timing of customer orders and contract wins.
Research funding pressures also remain relevant.
Academic and government research budgets can influence purchasing decisions for sequencing equipment and consumables.
The timing of large orders can therefore create quarter-to-quarter volatility.
Applied Markets Growth Is the Standout Positive
Perhaps the strongest part of the H1 update was Applied Markets.
Revenue increased approximately 22%.
Within that:
Clinical increased approximately 35%.
BioPharma increased approximately 25%.
Industrial increased approximately 5%.
This mix is strategically important.
Oxford Nanopore's long-term opportunity depends partly on moving its technology beyond research laboratories into larger-scale commercial and clinical applications.
Strong Clinical and BioPharma growth suggests progress in that direction.
Clinical Revenue Increased 35%
Clinical applications delivered approximately 35% revenue growth, making this one of the company's fastest-growing areas.
Sequencing can potentially support areas including disease research, pathogen analysis and increasingly sophisticated molecular diagnostics.
Oxford Nanopore's ability to produce sequencing information in real time can be particularly valuable where speed matters.
However, clinical markets also involve greater regulatory requirements.
Products may need approvals and validation before they can be used routinely in healthcare settings.
Therefore, the opportunity is substantial but commercialisation can take time.
BioPharma Revenue Increased 25%
BioPharma revenue increased approximately 25%.
Pharmaceutical and biotechnology companies use genomic technologies across drug discovery, development and manufacturing research.
These customers can be particularly attractive because successful adoption can lead to recurring usage across multiple programmes.
BioPharma customers may also have greater spending capacity than many academic laboratories.
Continued growth here could therefore improve both Oxford Nanopore's revenue mix and long-term commercial visibility.
Research Growth Slowed to 5%
Research revenue increased approximately 5% during H1.
The company said this reflected the previously communicated roll-off of several large projects.
Research remains extremely important to Oxford Nanopore because academic users frequently pioneer new applications for sequencing technology.
However, the relatively slower growth reinforces why diversification into Clinical, BioPharma and other Applied Markets is strategically valuable.
A broader revenue base reduces reliance on academic research budgets.
PromethION Revenue Increased 15%
Growth occurred across all product categories, led by PromethION, which increased approximately 15% year-on-year.
PromethION is Oxford Nanopore's higher-throughput sequencing platform.
High-throughput platforms are important for customers processing larger numbers of samples or requiring substantial sequencing capacity.
Increasing PromethION adoption can also generate recurring demand for consumables.
This installed-base model is important to Oxford Nanopore's longer-term economics.
Consumables Can Create Recurring Revenue
Sequencing platforms typically involve two broad revenue streams.
First, customers acquire or access sequencing equipment.
Second, they repeatedly purchase consumables required to run experiments.
As the installed base expands and existing customers increase utilisation, consumables revenue can grow.
This can potentially make future revenue more predictable.
The key metric is therefore not simply how many devices Oxford Nanopore places with customers, but how intensively those devices are subsequently used.
FY2026 Guidance Was Maintained
Despite the H1 disappointment, management maintained its expectation for 21–25% FY2026 constant-currency revenue growth.
However, investors should understand an important qualification.
The guidance incorporates additional collaboration and licensing revenue opportunities expected during H2, some of which may be non-recurring.
Excluding these additional opportunities, management expects constant-currency revenue growth of approximately 16–20%.
This distinction is crucial when evaluating the quality and sustainability of growth.
H2 Needs to Be Materially Stronger
Management expects a materially stronger second half.
That improvement is expected to come from continued Applied Markets momentum and the ramp-up of secured business.
This makes H2 execution particularly important.
Maintaining full-year guidance after a weaker-than-expected first half effectively increases the amount of performance that needs to be delivered later in the year.
Any further delays could therefore put FY2026 expectations under pressure.
Gross Margin Target Remains Around 62%
Oxford Nanopore maintained its FY2026 gross-margin guidance at approximately 62%.
Margin improvement is central to the pathway toward profitability.
As manufacturing efficiency improves and higher-margin revenue becomes a larger part of the mix, gross profit should ideally increase faster than operating expenses.
The company has already made meaningful progress.
FY2025 gross profit reached £131.3 million, up from £105.4 million in FY2024.
FY2027 EBITDA Breakeven Remains the Key Financial Target
Oxford Nanopore continues to expect adjusted EBITDA breakeven during FY2027.
This is arguably the most important medium-term financial milestone.
The company has spent heavily developing its technology, manufacturing capabilities and commercial infrastructure.
Investors now need evidence that increasing scale can translate into sustainable profitability.
Achieving EBITDA breakeven would represent an important transition from a development-heavy growth company toward a more financially self-sustaining business.
Losses Are Still Significant
Oxford Nanopore remains loss-making.
Its FY2025 annual report showed a £145.2 million loss for the year, broadly similar to the £146.2 million loss recorded in FY2024.
Adjusted EBITDA improved from a loss of £117.9 million in FY2024 to £86.7 million in FY2025.
That improvement demonstrates progress, but significant further work is required to reach breakeven.
Cost discipline and revenue growth therefore need to occur simultaneously.
Cash Position Remains Important
Cash, cash equivalents and other liquid investments stood at approximately £234.5 million at 30 June 2026, compared with £302.8 million at the end of FY2025.
The balance provides Oxford Nanopore with resources to continue investing in product development and commercial expansion.
However, the decline also illustrates why profitability matters.
A company cannot indefinitely fund operating losses by consuming cash reserves.
Progress toward FY2027 EBITDA breakeven is therefore important not only for valuation but also for long-term financial sustainability.
New CEO Adds Another Strategic Dimension
Oxford Nanopore entered a new leadership phase during 2026.
Founder Gordon Sanghera stepped down as CEO and from the board effective 2 March 2026, while remaining a senior adviser.
Francis Van Parys is now leading the company.
Leadership transitions can create uncertainty but also provide opportunities for sharper commercial execution and financial discipline.
Investors will therefore pay close attention to the strategy update accompanying the August results.
Key Growth Catalysts
Potential catalysts include stronger-than-expected H2 revenue, continued Clinical and BioPharma expansion and further PromethION adoption.
Additional collaboration and licensing agreements could support FY2026 growth.
Improved gross margins could accelerate progress toward profitability.
Large commercial or healthcare contracts could increase revenue visibility.
Expansion of sequencing applications could broaden the addressable market.
Successful product innovation could improve accuracy, throughput and affordability.
Most importantly, credible progress toward FY2027 EBITDA breakeven could materially change investor perceptions of the company's financial risk.
Risks Investors Continue to Monitor
China remains a significant near-term risk because export restrictions are affecting revenue.
Middle Eastern geopolitical disruption could continue.
Research funding pressures may constrain academic spending.
The company is still loss-making and consuming cash.
FY2026 guidance requires a significantly stronger second half.
Some expected H2 collaboration and licensing revenue may be non-recurring.
Competition in genomic sequencing remains intense.
Clinical adoption involves regulatory hurdles.
Technology evolves quickly, requiring continued research and development spending.
Finally, failure to achieve FY2027 EBITDA breakeven could raise concerns about longer-term financing requirements.
Valuation
Oxford Nanopore is more appropriately evaluated using growth-oriented metrics such as:
- Enterprise value to revenue
- Constant-currency revenue growth
- Gross margin
- Applied Markets growth
- Clinical and BioPharma growth
- Consumables revenue
- Installed platform base
- Adjusted EBITDA
- Cash burn
- Net cash
- Pathway to breakeven
Traditional P/E valuation is less useful while the company remains loss-making.
The central valuation debate is whether Oxford Nanopore can convert its differentiated technology and expanding commercial adoption into a profitable global sequencing platform.
Outlook
The outlook is promising but execution-sensitive.
H1 revenue growth disappointed management, primarily because of China, Middle Eastern disruption and order timing in the Americas.
Yet several underlying indicators were considerably stronger.
Applied Markets grew 22%, Clinical grew 35%, BioPharma increased 25%, and revenue outside China and the Middle East increased approximately 16% at constant currency.
Management also maintained its FY2026 revenue and margin guidance and its FY2027 EBITDA-breakeven target.
The next major test comes on 19 August, when Oxford Nanopore publishes its detailed interim results and CEO Francis Van Parys provides a strategy update.
Conclusion
As of 28 July 2026, Oxford Nanopore Technologies PLC (LSE:ONT) shares were up 2.21%.
No major fresh company announcement was identified on the day itself.
Instead, the gain appears more consistent with a partial recovery following the sharp reaction to the 13 July trading update and renewed investor focus on the stronger elements of Oxford Nanopore's underlying growth story.
H1 revenue is expected to reach approximately £116.5 million, up 10% reported and 12% at constant currency, although this was below management expectations.
The strongest evidence came from Applied Markets, where revenue increased approximately 22%, including 35% growth in Clinical and 25% in BioPharma.
Management has maintained its 21–25% FY2026 constant-currency growth guidance, approximately 62% gross-margin target and FY2027 adjusted EBITDA-breakeven ambition.
Therefore, the 2.21% rise on 28 July 2026 appears more like a recovery and pre-results positioning move than a reaction to a new same-day corporate catalyst.
The crucial question is whether the company can now deliver the materially stronger H2 required to justify its maintained full-year outlook.
Oxford Nanopore shares were up 2.21% on 28 July 2026. No major same-day corporate announcement was identified. The move appears more consistent with a partial recovery following the earlier H1 trading disappointment and investor positioning ahead of August results.
The company expects approximately £116.5 million, representing 10% reported growth and 12% constant-currency growth.
The main factors were weakness in China, disruption in the Middle East and timing of customer orders and contract wins in the Americas.
Clinical revenue increased approximately 35% during H1 2026.
BioPharma revenue increased approximately 25%.
Management continues to expect approximately 21–25% constant-currency growth, including additional collaboration and licensing opportunities.
The company continues to target adjusted EBITDA breakeven during FY2027.
Detailed H1 2026 results are scheduled for 19 August 2026, when management will also provide a strategy update.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...